Genmab A/S (NASDAQ:GMAB) Earns “Buy” Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of Genmab A/S (NASDAQ:GMAB) in a report issued on Tuesday, Benzinga reports. They currently have a $50.00 price target on the stock.

A number of other equities analysts have also recently issued reports on the company. Morgan Stanley reiterated an underweight rating on shares of Genmab A/S in a report on Tuesday, March 26th. BMO Capital Markets raised shares of Genmab A/S from a market perform rating to an outperform rating and boosted their price target for the stock from $46.00 to $48.00 in a research report on Friday, February 23rd. Truist Financial restated a buy rating and issued a $50.00 price objective on shares of Genmab A/S in a report on Tuesday, March 26th. Finally, Citigroup cut Genmab A/S from a neutral rating to a sell rating in a research report on Monday, January 22nd. Three equities research analysts have rated the stock with a sell rating, two have issued a hold rating and eight have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of Hold and an average target price of $48.50.

Genmab A/S Trading Up 7.2 %

GMAB stock opened at $29.72 on Tuesday. Genmab A/S has a 1-year low of $26.32 and a 1-year high of $42.72. The firm has a market cap of $19.65 billion, a PE ratio of 30.96, a P/E/G ratio of 2.07 and a beta of 1.00. The business’s 50-day moving average price is $29.38 and its two-hundred day moving average price is $29.92.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Wednesday, February 14th. The company reported $0.36 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.34 by $0.02. The business had revenue of $675.29 million during the quarter, compared to analysts’ expectations of $678.14 million. Genmab A/S had a return on equity of 18.06% and a net margin of 26.50%. On average, analysts forecast that Genmab A/S will post 1.06 earnings per share for the current year.

Institutional Investors Weigh In On Genmab A/S

Several hedge funds have recently added to or reduced their stakes in the business. Harding Loevner LP increased its holdings in shares of Genmab A/S by 2.7% in the fourth quarter. Harding Loevner LP now owns 3,289,895 shares of the company’s stock valued at $97,569,000 after purchasing an additional 85,665 shares during the last quarter. Wellington Management Group LLP grew its stake in Genmab A/S by 0.3% in the 3rd quarter. Wellington Management Group LLP now owns 2,425,381 shares of the company’s stock valued at $85,543,000 after buying an additional 8,244 shares during the last quarter. First Trust Advisors LP raised its holdings in Genmab A/S by 16.0% in the 4th quarter. First Trust Advisors LP now owns 1,270,095 shares of the company’s stock valued at $40,440,000 after acquiring an additional 175,292 shares during the period. Envestnet Asset Management Inc. lifted its position in Genmab A/S by 93.6% during the third quarter. Envestnet Asset Management Inc. now owns 946,880 shares of the company’s stock worth $33,396,000 after acquiring an additional 457,772 shares during the last quarter. Finally, Northern Trust Corp lifted its position in Genmab A/S by 83.3% during the third quarter. Northern Trust Corp now owns 559,044 shares of the company’s stock worth $19,717,000 after acquiring an additional 254,042 shares during the last quarter. Institutional investors and hedge funds own 7.07% of the company’s stock.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.